Faculty profile

David Lillicrap

ResearcherPathology and Molecular MedicineQueen's University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses may be missing. Find their university profile.

David Lillicrap

Researcher

Pathology and Molecular Medicine

Health Sciences

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
57 publications in the last five years, latest in 2026.
Senior (last) author on 16 recent papers, a sign of leading a research group.
Principal investigator on 11 research grants (11 CIHR), most recently in 2023.
Supervised 3 trainees who won CIHR awards, most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

167

Publications

222

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Molecular Biology Hemophilia Immunology Blood Bleeding Disorder Animal Models Inherited Bleeding Disorder Molecular Genetics

Latest papers

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.
Therapeutic advances in hematology · 2026 · senior author
Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.
Research and practice in thrombosis and haemostasis · 2026 · senior author
Molecular genetic testing in von Willebrand disease: past, present, and beyond.
Haematologica · 2026 · senior author

All 167 publications

Latest funding

Early genomic testing for inherited bleeding disorders in patients without a diagnosis after first-line testing: a randomized controlled trial
CIHR · 2023 · Principal investigator
$1,374,999
Uncovering a role for gut microbiota-derived short-chain fatty acids in the anti-Factor VIII immune response
CIHR · 2020 · Supervisor
$105,000
Personalized Medicine for Canadians with Hemophilia: a pragmatic evaluation of Web-Accessible Population Pharmacokinetics Service-Hemophilia (WAPPS-hemo) tailored dosing
CIHR · 2017 · Principal investigator
$256,274

All 16 grants and awards

From the 150 most recent of 167 publications.

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.

Fong S, Swystun LL, Batty P, Lillicrap D

Therapeutic advances in hematology2026Senior author

DOI: 10.1177/20406207251406537 PMID: 41624053

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Lund J, Ezban M, Jensen K, Lillicrap D

Research and practice in thrombosis and haemostasis2026Senior author

DOI: 10.1016/j.rpth.2025.103333 PMID: 41704799

Molecular genetic testing in von Willebrand disease: past, present, and beyond.

Seidizadeh O, Lillicrap D

Haematologica2026Senior author

DOI: 10.3324/haematol.2024.286014 PMID: 41496703

Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model.

Batty P, Swystun LL, Handyside B, Menard A, Harpell L, Hurlbut D, Ismail AM, Mo A, Pender A, Brennan S, Winterborn A, Yates B, Fong S, Lillicrap D

Journal of thrombosis and haemostasis : JTH2026Senior author

DOI: 10.1016/j.jtha.2026.08.014 PMID: 42628750

A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy.

Mussert CMA, Miesbach W, Chowdary P, Lillicrap D, Mahlangu J, Peyvandi F, Pipe SW, Srivastava A, Voorberg J, Pierce GF, Kaczmarek R, Batty P, Cutica I, Nathwani A, Leebeek FWG

Journal of thrombosis and haemostasis : JTH2026

DOI: 10.1016/j.jtha.2025.09.041 PMID: 41161417

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Matino D, Al-Housni Z, Samelson-Jones B, Chelle P, Castaman G, Teitel J, Jackson S, Lillicrap D, Keepanasseril A, Chan A

Journal of Thrombosis and Haemostasis2026

DOI: 10.1016/j.jtha.2026.08.010

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

Konkle BA, Peyvandi F, Foster GR, Hermans C, La Mura V, Leavitt AD, Lillicrap D, Mahlangu J, Ozelo MC, Pipe S, Recht M, Srivastava A, Young G, Miesbach W

Journal of thrombosis and haemostasis : JTH2025

DOI: 10.1016/j.jtha.2025.02.042 PMID: 40090623

A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.

Almeida MA, Diego VP, Viel KR, Luu BW, Haack K, Rajalingam R, Ameri A, Chitlur M, Rydz N, Lillicrap D, Watts RG, Kessler CM, Ramsey C, Dinh LV, Kim B, Powell JS, Manusov EG, Peralta JM, Bouls R, Abraham SM, Shen YM, Murillo CM, Mead H, Lehmann PV, Fine EJ, Escobar MA, Kumar S, Konkle BA, Williams-Blangero S, Kasper CK, Almasy L, Cole SA, Blangero J, Howard TE

Genes and immunity2025

DOI: 10.1038/s41435-025-00325-7 PMID: 40263602

Identification of multiple novel procoagulant plasma ligands for stabilin-2.

Underwood M, Da Veiga Leprevost F, Basrur V, Nesvizhskii AI, Rawley O, Golden K, Emmer B, Lillicrap D, Desch K

Journal of thrombosis and haemostasis : JTH2025

DOI: 10.1016/j.jtha.2025.01.023 PMID: 39970990

Genomic testing for bleeding disorders (GT4BD): protocol for a randomised controlled trial evaluating the introduction of whole genome sequencing early in the diagnostic pathway for patients with inherited bleeding disorders as compared with standard of care.

Chaigneau M, Bowman M, Grabell J, Conboy M, Johnson A, Thorpe K, Guerin A, Dinchong R, Paterson A, Good D, Mahar A, Callum J, Wheaton L, Leung J, Khalife R, Sholzberg M, Lillicrap D, James PD

BMJ open2025

DOI: 10.1136/bmjopen-2025-102041 PMID: 40246558

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Molecular Biology Dear Professor Lillicrap, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Early genomic testing for inherited bleeding disorders in patients without a diagnosis after first-line testing: a randomized controlled trial" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

David Lillicrap

Research

Latest papers

Latest funding

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Molecular genetic testing in von Willebrand disease: past, present, and beyond.

Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model.

A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy.

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.

Identification of multiple novel procoagulant plasma ligands for stabilin-2.

Genomic testing for bleeding disorders (GT4BD): protocol for a randomised controlled trial evaluating the introduction of whole genome sequencing early in the diagnostic pathway for patients with inherited bleeding disorders as compared with standard of care.

Frequent collaborators

Paula James

Alfonso Iorio

Davide Matino

Marc Carrier

Michael Fralick

Kevin Thorpe

Mark Skinner

Terence Tang

Jeannie Callum

Jennifer Leung

Yiming Wang

Robert Klaassen

Ana Johnson

Rosane Nisenbaum

Shinya Ito

Heyu Ni

Alyson Mahar

Catherine Pauline Ma Hayward

Irwin Ronald Walker

Gonzalo Hortelano

Peter Lawrence Gross

Kim Jones

Anthony Chan